UK-based Ignota Labs has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US company ceased operations earlier this year. Ignota specialises in turning around promising ...
For more than 40 years, the Kronos Quartet—David Harrington (violin), John Sherba (violin), Hank Dutt (viola), and Sunny Yang (cello)—has pursued a singular artistic vision, combining a spirit of ...
The NCAA Division I Administrative Committee approved on Tuesday two significant changes to the transfer portal, shrinking the amount of time granted to athletes to declare their intention to pursue a ...
Noble Kronos flagship IEMs deliver cutting-edge 9-driver hybrid sound with titanium shells. Are these $4,500 earphones worth the hype and price? Now, before you roll your eyes at the $4,500 price tag ...
Kronos is a HOLD: TiO2 demand should rise, but KRO lacks operating leverage and control over key feedstocks to benefit from upside. KRO faces significant competition from Chinese producers, especially ...
Investing.com -- S&P Global Ratings downgraded Concord, Ontario-based Kronos Acquisition Holdings Inc. to ’CCC+’ from ’B-’ due to tightening liquidity and ongoing operational challenges. The downgrade ...
It’s a question Asa Chandler hasn’t stopped asking since he heard his old friend Tony Kronos was missing. The 40-year-old was last seen at his residence in the 1600 block of Eleonora Street in Eagle ...
(RTTNews) - Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. NAMM 2025: Korg has revived its beloved Kronos workstation, unveiling an updated model that ...
Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...
Kronos Q324 sales volumes soared, offsetting flat TiO2 selling prices to deliver +22% YoY revenue growth along with improved profitability. The company faces high growth expectations as it integrates ...
On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results